KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Change in Cash (2020 - 2025)

Ginkgo Bioworks Holdings' Change in Cash history spans 6 years, with the latest figure at $55.4 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 199.31% year-over-year to $55.4 million; the TTM value through Dec 2025 reached -$393.4 million, down 2.48%, while the annual FY2025 figure was -$393.4 million, 2.48% down from the prior year.
  • Change in Cash reached $55.4 million in Q4 2025 per DNA's latest filing, up from -$94.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $1.5 billion in Q3 2021 to a low of -$250.3 million in Q1 2025.
  • Average Change in Cash over 5 years is -$8.7 million, with a median of -$90.5 million recorded in 2023.
  • Peak YoY movement for Change in Cash: plummeted 536.35% in 2023, then soared 199.31% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$172.4 million in 2021, then surged by 113.96% to $24.1 million in 2022, then tumbled by 536.35% to -$105.0 million in 2023, then skyrocketed by 46.88% to -$55.8 million in 2024, then skyrocketed by 199.31% to $55.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Change in Cash are $55.4 million (Q4 2025), -$94.4 million (Q3 2025), and -$104.1 million (Q2 2025).